Skip to main content

Month: March 2025

Satellogic Finalizes Move to U.S. Jurisdiction to Strengthen Market Position and Investor Access

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — On March 26, 2025, Satellogic Inc. (NASDAQ: SATL) (the “Company”), consummated its previously announced domestication, pursuant to which the Company changed its jurisdiction of incorporation, domesticating as a corporation incorporated under the laws of the State of Delaware and discontinuing as a business company with limited liability incorporated under the laws of the British Virgin Islands. The Company’s business, assets and liabilities on a consolidated basis, as well as its Board of Directors, the Company’s executive officers, principal business locations (other than its principal executive office) and fiscal year, were the same immediately after the domestication as they were immediately prior to the domestication. Additionally, the Company’s Class A common stock will continue...

Continue reading

Invesco Ltd: Form 8.3 – NIOX Group PLC; Public dealing disclosure

FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Invesco Ltd.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree NIOX Group plc  (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:    (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to...

Continue reading

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR. Poster 1: Title: Bria-ABC1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4/30/2025 9:00 AM –...

Continue reading

OSS Announces Order from Innovative Medical Imaging OEM

Current contract valued at approximately $500,000 with expected follow-on production orders valued at over $25 million over the next five years ESCONDIDO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced a new $500,000 contract from a medical imaging OEM customer that is expected to contribute to revenue throughout 2025. Under the terms of the contract, OSS will provide 4U, short-depth-server (SDS) running Enterprise Class NVIDIA GPUs to support a customer’s innovative, FDA cleared, medical imaging technology for Breast Scanning. After this initial order, OSS expects follow-on orders from this medical OEM for next-generation liquid-cooled...

Continue reading

National Healthcare Properties Announces Preferred Stock Dividends

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, NHP declared a dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock payable on April 15, 2025 to holders of record at the close of business on April 4, 2025. In addition, NHP declared a dividend of $0.4453125 per share on its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock payable on April 15, 2025 to holders of record at the close of business on April 4, 2025. About National Healthcare Properties, Inc. National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) is a publicly registered real estate investment trust focused on acquiring a diversified...

Continue reading

Zelluna ASA [ZLNA]: Share capital increase resolution

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the “Company“), where it was resolved to carry out a reverse share split in the ratio 10:1 and to grant the Company’s board of directors a general authorisation to issue shares. As the Company’s shares cannot be fully divided by 10, the Company’s board of directors has today resolved a share capital increase of NOK 0.70 through the issuance of seven (7) new shares, each with a par value of NOK 0.10, and a subscription price of NOK 2.60 per share. The shares were subscribed for by Radforsk Investeringsstiftelse. A separate notification regarding transaction by persons discharging managerial responsibilities (PDMRs) will be published shortly....

Continue reading

TRANSFER OF HARVIA’S OWN SHARES AS REWARDS UNDER THE INCENTIVE PROGRAM

HARVIA PLC                                  STOCK EXCHANGE RELEASE                                 March 26, 2025 AT 2.15 P.M. EET   The Board of Directors of Harvia Plc has on 25 February 2025 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2022–2024 of the company’s share-based incentive program launched in 2022. In the share issue, 9,852 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the terms and conditions of the program. The company holds a total of 5,355 own shares after the transfer of shares under the incentive program. The decision on the transfer of shares is...

Continue reading

SAIC Announces ReadyOne™ Foundational: Latest Digital Engineering Ecosystem for Accelerated Innovation and Mission Effectiveness

RESTON, Va., March 26, 2025 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) has announced the launch of ReadyOne™ Foundational – the company’s commercial-grade solution for a rapidly deployable, cloud-based digital engineering ecosystem that meets the Department of Defense (DoD) Instruction 5000.97 mandate and unique mission requirements of government customers. It is now available on the AWS Marketplace to accelerate deployment and help government avoid developing capabilities that are already commercially available. ReadyOne™ Foundational’s built-in digital thread accelerator unifies disparate data, tools and teams in real-time through a configurable, turnkey solution – enabling an out-of-the-box adoption of best practices in digital engineering. This offering grants customers access...

Continue reading

VERSES® Announces Consolidation of Class A Subordinate Voting Shares in Preparation for a Planned Uplisting to NASDAQ

VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) a cognitive computing company specializing in next-generation intelligent software systems, is pleased to announce the consolidation of its Class A Subordinated Voting Shares in connection with an application to uplist such shares on the Nasdaq Capital Market (“Nasdaq”). As part of the planned uplisting, the Company is consolidating all issued and outstanding Class A Subordinate Voting Shares (“Subordinated Voting Shares”) on the basis of one (1) post-consolidated Subordinated Voting Share for every nine (9) pre-consolidated Subordinated Voting Share held (the “Consolidation”). “The consolidation is one of many initiatives that the Company is implementing in preparation for our intended...

Continue reading

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. “2024 was a year of focused execution and strategic advancement at Mereo, driving our lead programs closer to key milestones,” said Dr. Denise Scots-Knight, Chief Executive Officer...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.